A detailed history of Pinnacle Bancorp, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Pinnacle Bancorp, Inc. holds 971 shares of GMAB stock, worth $19,992. This represents 0.01% of its overall portfolio holdings.

Number of Shares
971
Previous 971 -0.0%
Holding current value
$19,992
Previous $24,000 4.17%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

BUY
$26.43 - $32.77 $3,462 - $4,292
131 Added 15.6%
971 $29,000
Q4 2023

Jan 25, 2024

BUY
$27.94 - $35.44 $17,825 - $22,610
638 Added 315.84%
840 $26,000
Q3 2022

Oct 25, 2022

SELL
$31.52 - $373.61 $914 - $10,834
-29 Reduced 12.55%
202 $6,000
Q3 2021

Oct 12, 2021

BUY
$41.55 - $48.72 $9,598 - $11,254
231 New
231 $10,000
Q1 2021

Apr 26, 2021

SELL
$30.92 - $44.4 $4,576 - $6,571
-148 Closed
0 $0
Q3 2020

Oct 13, 2020

BUY
$33.07 - $38.68 $4,894 - $5,724
148 New
148 $5,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Pinnacle Bancorp, Inc. Portfolio

Follow Pinnacle Bancorp, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Bancorp, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Bancorp, Inc. with notifications on news.